Fludarabine: A Review of its Use in Non-Hodgkin's Lymphoma

By Anderson Vanessa R.   Perry Caroline M.  

Drugs, Vol. 67, Iss. 11, 2007-01 ,pp. : 1633-1655

Adis International

Access to resources Recommend Favorite

Effect of the Cytochrome P450 2C19 Inhibitor Omeprazole on the Pharmacokinetics and Safety Profile of Bortezomib in Patients with Advanced Solid Tumours, Non-Hodgkin's Lymphoma or Multiple Myeloma

By Quinn David I.  

Clinical Pharmacokinetics, Vol. 48, Iss. 3, 2009-01 ,pp. : 199-209

Adis International

Access to resources Recommend Favorite

Fludarabine–Mitoxantrone–Rituximab regimen in untreated indolent non‐follicular non‐Hodgkin's lymphoma: experience on 143 patients

By  

Hematological Oncology (Electronic), Vol. 278-0232, Iss. 3, 2015-09 ,pp. : 141-146

John Wiley & Sons Inc

Access to resources Recommend Favorite

Fludarabine–Mitoxantrone–Rituximab regimen in untreated indolent non‐follicular non‐Hodgkin's lymphoma: experience on 143 patients

By  

Hematological Oncology (Electronic), Vol. 33, Iss. 3, 2015-09 ,pp. : 141-146

John Wiley & Sons Inc

Access to resources Recommend Favorite

Renal Insufficiency Has No Effect on the Pharmacokinetics of Vicriviroc in a Ritonavir-Containing Regimen

By Kasserra Claudia  

Clinical Pharmacokinetics, Vol. 49, Iss. 6, 2010-06 ,pp. : 397-406

Adis International

Access to resources Recommend Favorite